Loading...
XNASFDMT
Market cap216mUSD
Jan 16, Last price  
4.68USD
1D
-7.14%
1Q
-45.13%
IPO
-88.44%
Name

4D Molecular Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:FDMT chart
P/E
—
P/S
10.44
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
25.60%
Rev. gr., 5y
7.96%
Revenues
21m
+562.29%
5,790,00014,130,0006,986,00013,612,00018,038,0003,129,00020,723,000
Net income
-101m
L-0.24%
-11,223,000-9,551,000-52,939,000-56,541,000-68,297,000-101,076,000-100,837,000
CFO
-76m
L-12.57%
8,237,000-16,252,000-36,711,000-50,909,000-69,134,000-86,685,000-75,792,000
Earnings
Feb 26, 2025

Profile

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
URL
https://4dmoleculartherapeutics.com/
IPO date
Dec 11, 2020
Employees
137
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
20,723
562.29%
3,129
-82.65%
Cost of revenue
230,686
117,041
Unusual Expense (Income)
NOPBT
(209,963)
(113,912)
NOPBT Margin
Operating Taxes
(6,418)
Tax Rate
NOPAT
(209,963)
(107,494)
Net income
(100,837)
-0.24%
(101,076)
47.99%
Dividends
Dividend yield
Proceeds from repurchase of equity
148,344
2,730
BB yield
-18.71%
-0.38%
Debt
Debt current
6,298
2,655
Long-term debt
26,193
29,593
Deferred revenue
972
1,076
Other long-term liabilities
617
233
Net debt
(266,695)
(191,302)
Cash flow
Cash from operating activities
(75,792)
(86,685)
CAPEX
(2,771)
(11,536)
Cash from investing activities
115,717
(17,050)
Cash from financing activities
156,832
3,085
FCF
(206,281)
(113,888)
Balance
Cash
288,232
218,642
Long term investments
10,954
4,908
Excess cash
298,150
223,394
Stockholders' equity
(415,307)
(315,683)
Invested Capital
742,545
18,626
ROIC
ROCE
EV
Common stock shares outstanding
39,130
32,351
Price
20.26
-8.78%
22.21
1.23%
Market cap
792,775
10.33%
718,521
18.10%
EV
526,080
527,219
EBITDA
(204,214)
(110,032)
EV/EBITDA
Interest
6,418
Interest/NOPBT